CA3227102A1 - Anandamide cyclodextrin inclusion complex vehicles - Google Patents
Anandamide cyclodextrin inclusion complex vehicles Download PDFInfo
- Publication number
- CA3227102A1 CA3227102A1 CA3227102A CA3227102A CA3227102A1 CA 3227102 A1 CA3227102 A1 CA 3227102A1 CA 3227102 A CA3227102 A CA 3227102A CA 3227102 A CA3227102 A CA 3227102A CA 3227102 A1 CA3227102 A1 CA 3227102A1
- Authority
- CA
- Canada
- Prior art keywords
- cyclodextrin
- citrulline
- inclusion complex
- anandamide
- complex formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01011—Dextranase (3.2.1.11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163229447P | 2021-08-04 | 2021-08-04 | |
| US63/229,447 | 2021-08-04 | ||
| PCT/IB2022/056550 WO2023012552A1 (en) | 2021-08-04 | 2022-07-15 | Anandamide cyclodextrin inclusion complex vehicles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3227102A1 true CA3227102A1 (en) | 2023-02-09 |
Family
ID=85155427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3227102A Pending CA3227102A1 (en) | 2021-08-04 | 2022-07-15 | Anandamide cyclodextrin inclusion complex vehicles |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250205181A1 (enExample) |
| EP (1) | EP4380556A4 (enExample) |
| JP (1) | JP2024528990A (enExample) |
| KR (1) | KR20240050356A (enExample) |
| CN (1) | CN118043040A (enExample) |
| AU (1) | AU2022323827A1 (enExample) |
| CA (1) | CA3227102A1 (enExample) |
| IL (1) | IL310613A (enExample) |
| WO (1) | WO2023012552A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024199007A1 (zh) * | 2023-03-28 | 2024-10-03 | 南京纽邦生物科技有限公司 | 花生四烯酸乙醇胺组合物 |
| WO2025229618A1 (en) * | 2024-05-02 | 2025-11-06 | Czap Research And Development, Llc | Blood glucose control with enzymatic cyclodextrin inclusion complex formulations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996001558A1 (en) * | 1994-07-11 | 1996-01-25 | Pate David W | Anandamide analogue compositions and method of treating intraocular hypertention using same |
| US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
| US20170224841A1 (en) * | 2016-02-04 | 2017-08-10 | Czap Reseach And Development, Llc | Controlled-release and stratified cyclodextrin inclusion complex vehicles |
| JP7758353B2 (ja) * | 2020-03-23 | 2025-10-22 | クザップ リサーチ アンド デベロップメント エルエルシー | 経口テルペンシクロデキストリン包接体ビヒクル |
-
2022
- 2022-07-15 IL IL310613A patent/IL310613A/en unknown
- 2022-07-15 AU AU2022323827A patent/AU2022323827A1/en active Pending
- 2022-07-15 CN CN202280066092.6A patent/CN118043040A/zh active Pending
- 2022-07-15 US US18/294,821 patent/US20250205181A1/en active Pending
- 2022-07-15 CA CA3227102A patent/CA3227102A1/en active Pending
- 2022-07-15 JP JP2024506685A patent/JP2024528990A/ja active Pending
- 2022-07-15 EP EP22852410.4A patent/EP4380556A4/en active Pending
- 2022-07-15 KR KR1020247007312A patent/KR20240050356A/ko active Pending
- 2022-07-15 WO PCT/IB2022/056550 patent/WO2023012552A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024528990A (ja) | 2024-08-01 |
| EP4380556A4 (en) | 2025-07-02 |
| WO2023012552A1 (en) | 2023-02-09 |
| EP4380556A1 (en) | 2024-06-12 |
| AU2022323827A1 (en) | 2024-02-15 |
| US20250205181A1 (en) | 2025-06-26 |
| CN118043040A (zh) | 2024-05-14 |
| IL310613A (en) | 2024-04-01 |
| KR20240050356A (ko) | 2024-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12285455B2 (en) | Controlled-release and stratified cyclodextrin inclusion complex vehicles | |
| US20200347153A1 (en) | Methods for forming inclusion complexes with hydrophilic beta-cyclodextrin derivatives and compositions thereof | |
| US11779561B2 (en) | Compounds and pharmaceutical uses thereof | |
| EP4125830B1 (en) | Oral terpene cyclodextrin inclusion complex vehicles | |
| CN101534794A (zh) | 用于递送眼科用药物的凝胶 | |
| JP5021305B2 (ja) | 水溶性ジテルペンの調製方法およびその適用 | |
| WO2023012552A1 (en) | Anandamide cyclodextrin inclusion complex vehicles | |
| US20170224841A1 (en) | Controlled-release and stratified cyclodextrin inclusion complex vehicles | |
| EP4309642A1 (en) | Liquid preparation of l-serine or pharmaceutically acceptable salt thereof and method for preparing same | |
| CN117430541B (zh) | 用于向细胞递送的化合物及其组合物 | |
| US20170224842A1 (en) | Controlled-release and stratified cyclodextrin inclusion complex vehicles | |
| JP2005515982A (ja) | ２−ヒドロキシプロピル−β−シクロデキストリンによるタキソールの包接錯体 | |
| JP7623953B2 (ja) | 医薬品または化粧品用組成物 | |
| WO2025229618A1 (en) | Blood glucose control with enzymatic cyclodextrin inclusion complex formulations | |
| WO2025229633A2 (en) | Arterial plaque control with enzymatic cyclodextrin inclusion complex formulations | |
| WO2025238557A1 (en) | Cholesterol control with enzymatic cyclodextrin inclusion complex formulations | |
| US20250009698A1 (en) | Nervonic acid-based compositions and methods | |
| HK40082169B (zh) | 口服萜烯环糊精包合物媒介物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |